Clinical Trial Update: Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ezetimibe-ursodiol combination therapy on liver function biomarkers and sterol balance in nonalcoholic fatty liver disease (NAFLD) was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• ezetimibe-ursodiol combination therapy

Snippet

Sponsor: Gregory Graf, PhD | Conditions: Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Status: TERMINATED | Results posted: 2018-02-07